Press Releases / Notices

Johnson & Johnson Obtains Approval for YUVANCI ® Combination Tablet for the Treatment of Pulmonary Arterial Hypertension

Nippon Shinyaku and Capricor Therapeutics Execute Letter of Intent for Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Europe

FDA Grants Rare Pediatric Disease Designation to NS-050/NCNP-03 for the Treatment of Duchenne Muscular Dystrophy

Antineoplastic agents Released "Jaypirca® Tablets 50 mg, Jaypirca® Tablets 100 mg"

Notice Regarding Completion of Disposal of Treasury Stock as Restricted Stock Compensation

Revision of Performance Projection

Outline of Consolidated Financial Results for the First Quarter Ended June 30, 2024

Nippon Shinyaku Selected as a Constituent of the FTSE4Good Index Series

Notice Regarding Disposal of Treasury Stock as Restricted Stock Compensation

Nippon Shinyaku Selected as a Constituent of the SOMPO Sustainability Index

Japan’s PMDA approves Antineoplastic Agent "Jaypirca® 50 mg and 100 mg tablets" for Patients with Relapsed or Refractory MCL Who are Resistant or Intolerant to Other BTK Inhibitors

Notice Of The 161st Annual General Meeting Of Shareholders

The 7th Five-Year Medium-Term Management Plan "For Global Growth Beyond the Cliff”

Viltolarsen (NS-065/NCNP-01) for the treatment of Duchenne Muscular Dystrophy Preliminary Results of the Analysis of the Phase III Trial (RACER53 Study)

Notice Regarding Introduction of a Restricted Stock Compensation Plan

Launch of VyxeosⓇ Combination for I.V. Injection for the Treatment of High-risk AML in Japan

Outline of Consolidated Financial Results for the Year Ended March 31, 2024

Nippon Shinyaku Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW

Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System

UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan

Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan

Announcement of Alliance Agreement for Pirtobrutinib, a Reversible Non-Covalent BTK Inhibitor in Japan

VILTEPSO® (viltolarsen) injection: Phase II trial (Galactic53 trial) Data presented at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

VILTEPSO® (viltolarsen) injection: Phase II trial (Galactic53 trial) Data Scheduled for Presentation at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Nippon Shinyaku and Vicore Pharma enter into an Exclusive License Agreement to Develop and Commercialize C21 for the treatment of Idiopathic Pulmonary Fibrosis in Japan

Outline of Consolidated Financial Results for the Third Quarter Ended December 31, 2023

Nippon Shinyaku's Greenhouse Gas Emission Reduction Targets Approved by SBTi

The European Commission Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis